Crispr Therapeutics AG (1CG) Ownership - Who Owns Crispr Therapeutics AG?
Crispr Therapeutics AG (1CG) Ownership Overview
- 2.61% Insiders
- 13.70% Mutual Funds
- 2.55% Other Institutional Investors
- 20.38% ETFs
- 60.75% Public Companies and Individual Investors
The ownership structure of Crispr Therapeutics AG (DE:1CG) stock is a mix of institutional, retail, and individual investors. Approximately 36.63% of the company’s stock is owned by Institutional Investors, 2.61% is owned by Insiders, and 60.75% is owned by Public Companies and Individual Investors.
The ownership structure of Crispr Therapeutics AG (DE:1CG) stock is a mix of institutional, retail, and individual investors. Approximately 16.25% of the company’s stock is owned by Institutional Investors, 2.61% is owned by Insiders, and 20.38% is owned by Public Companies and Individual Investors.
Recent Insider Trading Activity
| Date | Name | Activity | Value |
|---|---|---|---|
| Sep 20, 2026 | Ali Behbahani | $780,934 | |
| Jan 26, 2026 | Naimish Patel | $49,704 |
Recent Hedge Fund Trading Activity
| Date | Firm | Activity | Value |
|---|---|---|---|
| Dec 31, 2025 | Elkhorn Partners Limited Partnership | €87,050 | |
| Dec 31, 2025 | No Street Gp Lp | €6,555,000 | |
| Dec 31, 2025 | Ark Investment Management Llc | €551,776,669 |
Top Shareholders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| Cathie Wood | 9,460,939 | Institution | 9.78% | 489,158,929 |
| Ark | 8,055,487 | Institution | 8.33% | 416,492,844 |
| Ishares | 4,563,057 | Institution | 4.72% | 235,923,736 |
| Spdr | 3,235,746 | Institution | 3.35% | 167,297,775 |
| Simeon George | 2,054,249 | Insider | 2.12% | 106,210,836 |
| New Perspective Fund | 1,944,073 | Institution | 2.01% | 100,514,406 |
| Vanguard | 1,810,558 | Institution | 1.87% | 93,611,280 |
| Smallcap World Fund Inc | 1,694,327 | Institution | 1.75% | 87,601,789 |
| Growth Fund Of America | 1,414,053 | Institution | 1.46% | 73,110,782 |
| Fidelity Salem Street Trust | 1,159,051 | Institution | 1.20% | 59,926,414 |
Top Mutual Fund Holders
| Holder | # of Shares | Type | % Holding | Value |
|---|---|---|---|---|
| New Perspective Fund | 1,944,073 | Institution | 2.01% | 100,514,406 |
| Smallcap World Fund Inc | 1,694,327 | Institution | 1.75% | 87,601,789 |
| Growth Fund Of America | 1,414,053 | Institution | 1.46% | 73,110,782 |
| Fidelity Salem Street Trust | 1,159,051 | Institution | 1.20% | 59,926,414 |
| Vanguard Index Funds | 1,106,745 | Institution | 1.14% | 57,222,037 |
| T. Rowe Price Mid-cap Growth Fund, Inc. | 1,050,191 | Institution | 1.09% | 54,298,025 |
| Fidelity Concord Street Trust | 946,149 | Institution | 0.98% | 48,918,742 |
| Fidelity Mt. Vernon Street Trust | 861,194 | Institution | 0.89% | 44,526,313 |
| Vanguard Scottsdale Funds | 631,378 | Institution | 0.65% | 32,644,137 |
| T. Rowe Price Quantitative Management Funds, Inc. | 351,358 | Institution | 0.36% | 18,166,263 |
FAQ
Who Owns Crispr Therapeutics AG (DE:1CG)?
According to the latest TipRanks data, approximately 2.55% of the company's stock is held by institutional investors, 2.61% is held by insiders, and 60.75% is held by retail investors.
What percentage of Crispr Therapeutics AG (DE:1CG) stock is held by institutional investors?
According to the latest TipRanks data, approximately 2.55% of Crispr Therapeutics AG (DE:1CG) stock is held by institutional investors.
What percentage of Crispr Therapeutics AG (DE:1CG) stock is held by retail investors?
According to the latest TipRanks data, approximately 60.75% of Crispr Therapeutics AG (DE:1CG) stock is held by retail investors.
Who owns the most shares of Crispr Therapeutics AG (DE:1CG)?
Cathie Wood owns the most shares of Crispr Therapeutics AG (DE:1CG).
What is the significance of the ownership structure for a publicly traded company?
The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.